727 FinancePANews October 21 news, according to an official OpenAI announcement, OpenAI has acquired Orchestra Bio, a drug R&D collaboration platform. The platform helps biopharmaceutical teams coordinate complex drug development processes, allowing scientists and project leads to delegate the monitoring and tracking of research and trials to AI agents. OpenAI stated that it will integrate Orchestra's team and technology with Rosalind, its life sciences research AI model and tool, to help new therapies reach patients faster.
OpenAI acquires drug R&D collaboration platform Orchestra Bio
Actualités liées
Financement Hebdomadaire | Kalshi boucle un financement de série G de 1 milliard de dollars, mené par Sequoia Capital et Wellington Management.
Kalshi a finalisé un tour de financement de série G de 1 milliard de dollars, atteignant une valorisation post-money de 40 milliards de dollars, soit près du do...